D. Rivera

Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Leukemia & lymphoma.

Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy

E. Colado, Marcos González, A. Órfão, 2018, Modern Pathology.

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Leukemia & lymphoma.

Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies

A. Ferrajoli, D. Rivera, 2022, Current Oncology Reports.

Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

J. González-Porras, F. Sánchez-Guijo, M. Caballero, 2018, Bone Marrow Transplantation.

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.

C. de Miguel, C. Solano, J. González-Porras, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

M. Konopleva, M. Andreeff, K. Bhalla, 2020 .

Leukemic phase follicular lymphoma in a young adult

Z. Hu, Wei Wang, D. Rivera, 2023, Journal of clinical laboratory analysis.